Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Galmed Pharmaceuticals Ltd. (GLMD) had Stock-Based Compensation of $0.31M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.89M |
|
-- |
|
-- |
|
$2.10M |
|
$-2.10M |
|
$0.20M |
|
$-1.89M |
|
$-1.89M |
|
$-1.89M |
|
$-1.89M |
|
$-1.89M |
|
$-1.89M |
|
$-2.10M |
|
$-2.09M |
|
5.46M |
|
5.46M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$19.72M |
|
-- |
|
$1.86M |
|
$21.58M |
|
$2.47M |
|
-- |
|
-- |
|
$2.47M |
|
$19.11M |
|
$19.11M |
|
$19.11M |
|
5.48M |
|
| Cash Flow Statement Financials | |
$-4.37M |
|
$-4.80M |
|
$7.84M |
|
$4.77M |
|
$3.44M |
|
$-1.33M |
|
|
Stock-Based Compensation |
$0.31M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.37M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.90% |
|
-9.90% |
|
-8.77% |
|
-9.90% |
|
$3.49 |
|
$-0.80 |
|
$-0.80 |
|